Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial
Titel:
Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial
Auteur:
Laterre, Pierre-François Pickkers, Peter Marx, Gernot Wittebole, Xavier Meziani, Ferhat Dugernier, Thierry Huberlant, Vincent Schuerholz, Tobias François, Bruno Lascarrou, Jean-Baptiste Beishuizen, Albertus Oueslati, Haikel Contou, Damien Hoiting, Oscar Lacherade, Jean-Claude Chousterman, Benjamin Pottecher, Julien Bauer, Michael Godet, Thomas Karakas, Mahir Helms, Julie Bergmann, Andreas Zimmermann, Jens Richter, Kathleen Hartmann, Oliver Pars, Melanie Mebazaa, Alexandre ,